{"id":8921,"date":"2021-03-15T02:43:48","date_gmt":"2021-03-14T22:43:48","guid":{"rendered":"http:\/\/veteran.az\/?p=8921"},"modified":"2021-03-15T02:43:49","modified_gmt":"2021-03-14T22:43:49","slug":"%c9%99lilliyin-v%c9%99-saglamliq-imkanlarinin-m%c9%99hdudlugunun-mu%c9%99yy%c9%99n-olunmasi-meyarlarina-dair-%c9%99sasnam%c9%99","status":"publish","type":"post","link":"https:\/\/veteran.az\/?p=8921","title":{"rendered":"\u201c\u018flilliyin v\u0259 sa\u011flaml\u0131q imkanlar\u0131n\u0131n m\u0259hdudlu\u011funun m\u00fc\u0259yy\u0259n olunmas\u0131 meyarlar\u0131na dair \u018fsasnam\u0259\u201d"},"content":{"rendered":"\n
Az\u0259rbaycan Respublikas\u0131 Nazirl\u0259rKabinetinin 2015-ci il 30 dekabr tarixli 413 n\u00f6mr\u0259li q\u0259rar\u0131 il\u0259 t\u0259sdiq edilmi\u015fdir<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

1. \u00dcmumi m\u00fcdd\u0259alar<\/strong><\/p>\n\n\n\n

1.1. \u018flill\u0259r\u0259 m\u00fcnasib\u0259t sah\u0259sind\u0259 sosial siyas\u0259t h\u0259yatda v\u0259 c\u0259miyy\u0259tin inki\u015faf\u0131nda onlar\u0131n f\u0259al i\u015ftirak etm\u0259si imkanlar\u0131n\u0131n geni\u015fl\u0259ndirilm\u0259sin\u0259, sosial rifah hal\u0131n\u0131n, maddi v\u0259ziyy\u0259tl\u0259rinin yax\u015f\u0131la\u015fd\u0131r\u0131lmas\u0131na y\u00f6n\u0259ldilmi\u015fdir.<\/p>\n\n\n\n

1.2. \u018flillik v\u0259 ya 18 ya\u015f\u0131nad\u0259k u\u015faqlar\u0131n sa\u011flaml\u0131q imkanlar\u0131n\u0131n m\u0259hdudlu\u011fu \u015f\u0259xsin tibbi-sosial ekspertiza m\u00fcayin\u0259sind\u0259n ke\u00e7iril\u0259r\u0259k, \u201c\u018flilliyin v\u0259 u\u015faqlar\u0131n sa\u011flaml\u0131q imkanlar\u0131 m\u0259hdudlu\u011funun qar\u015f\u0131s\u0131n\u0131n al\u0131nmas\u0131, \u0259lill\u0259rin v\u0259 sa\u011flaml\u0131q imkanlar\u0131 m\u0259hdud u\u015faqlar\u0131n reabilitasiyas\u0131 v\u0259 sosial m\u00fcdafi\u0259si haqq\u0131nda\u201d Az\u0259rbaycan Respublikas\u0131n\u0131n Qanununa uy\u011fun olaraq anadang\u0259lm\u0259, x\u0259st\u0259likd\u0259n v\u0259 ya x\u0259sar\u0259td\u0259n yaranan \u0259qli v\u0259 ya fiziki q\u00fcsurlar n\u0259tic\u0259sind\u0259 h\u0259yat f\u0259aliyy\u0259tinin m\u0259hdudla\u015fmas\u0131 haqq\u0131nda m\u00fcvafiq q\u0259rar \u00e7\u0131xar\u0131lmas\u0131 yolu il\u0259 m\u00fc\u0259yy\u0259n olunur.<\/p>\n\n\n\n

1.3. Tibbi-sosial ekspertiza m\u00fcayin\u0259si tibbi etika v\u0259 deontologiya prinsipl\u0259rin\u0259 \u0259saslanmaqla h\u0259yata ke\u00e7irilir. \u015e\u0259xsin dig\u0259r \u015f\u0259xsl\u0259rl\u0259 b\u0259rab\u0259r s\u0259viyy\u0259d\u0259 c\u0259miyy\u0259td\u0259 tam v\u0259 s\u0259m\u0259r\u0259li i\u015ftirak\u0131na mane olan fiziki, psixi, \u0259qli v\u0259 ya hissiyyat pozuntular\u0131n\u0131n olmas\u0131n\u0131, sa\u011flaml\u0131q v\u0259ziyy\u0259tini v\u0259 sosial uy\u011funla\u015fma d\u0259r\u0259c\u0259sini m\u00fc\u0259yy\u0259n etm\u0259k \u00fc\u00e7\u00fcn funksional v\u0259 laboratoriya m\u00fcayin\u0259l\u0259rinin n\u0259tic\u0259l\u0259ri anamnestik m\u0259lumatlar obyektiv qiym\u0259tl\u0259ndirilir.<\/p>\n\n\n\n

1.4. \u018flillik v\u0259 ya 18 ya\u015f\u0131nad\u0259k u\u015faqlar\u0131n sa\u011flaml\u0131q imkanlar\u0131n\u0131n m\u0259hdudlu\u011fu bar\u0259d\u0259 q\u0259rar klinik, psixoloji, sosial-m\u0259i\u015f\u0259t, pe\u015f\u0259 amill\u0259rinin v\u0259 \u015f\u0259xsin reabilitasiya potensial\u0131n\u0131n kompleks halda qiym\u0259tl\u0259ndirilm\u0259sin\u0259 \u0259saslan\u0131r. Bu zaman x\u0259st\u0259liyin xarakteri, funksiyalar\u0131n pozulma d\u0259r\u0259c\u0259si, m\u00fcalic\u0259nin v\u0259 reabilitasiya t\u0259dbirl\u0259rinin s\u0259m\u0259r\u0259liliyi, orqanizmin kompensator (\u0259v\u0259zetm\u0259) mexanizml\u0259rinin v\u0259ziyy\u0259ti, klinik v\u0259 \u0259m\u0259k proqnozlar\u0131, sosial uy\u011funla\u015fma (adaptasiya) imkanlar\u0131, sosial yard\u0131ma v\u0259 m\u00fcdafi\u0259y\u0259 ehtiyac\u0131 olmas\u0131, \u0259m\u0259k \u015f\u0259raiti, i\u015finin mahiyy\u0259ti, pe\u015f\u0259 haz\u0131rl\u0131\u011f\u0131 v\u0259 ya\u015f\u0131 n\u0259z\u0259r\u0259 al\u0131n\u0131r.<\/p>\n\n\n\n

1.5. Tibbi-sosial ekspert komissiyalar\u0131 t\u0259r\u0259find\u0259n birinci, ikinci v\u0259 \u00fc\u00e7\u00fcnc\u00fc d\u0259r\u0259c\u0259 \u0259lillik v\u0259 18 ya\u015f\u0131nad\u0259k u\u015faqlara m\u00fcnasib\u0259td\u0259 sa\u011flaml\u0131q imkanlar\u0131n\u0131n m\u0259hdudlu\u011fu m\u00fc\u0259yy\u0259n olunur.<\/p>\n\n\n\n

2. \u018flilliyin m\u00fc\u0259yy\u0259n olunmas\u0131 meyarlar\u0131<\/strong><\/p>\n\n\n\n

2.1. Birinci d\u0259r\u0259c\u0259 \u0259lillik — x\u0259st\u0259lik, travma v\u0259 ya anadang\u0259lm\u0259 q\u00fcsurlar n\u0259tic\u0259sind\u0259 orqanizmin h\u0259yat f\u0259aliyy\u0259tinin (t\u0259hsilalma, \u00fcnsiyy\u0259t, sosial uy\u011funla\u015fma, \u00f6z davran\u0131\u015f\u0131na n\u0259zar\u0259tetm\u0259, h\u0259r\u0259k\u0259tetm\u0259, \u00f6z\u00fcn\u0259 xidm\u0259tetm\u0259, \u0259m\u0259k f\u0259aliyy\u0259ti) el\u0259 k\u0259skin m\u0259hdudla\u015fmas\u0131 hallar\u0131nda t\u0259yin edilir ki, h\u0259min x\u0259st\u0259nin k\u0259nar \u015f\u0259xsin yard\u0131m v\u0259 ya qullu\u011funa daimi ehtiyac\u0131 olsun. Q\u00fcsurlar\u0131n v\u0259 ya funksiya pozuntular\u0131n\u0131n x\u00fcsusi vasit\u0259l\u0259rl\u0259 kompensasiya olundu\u011fu hallarda \u0259lil \u015f\u0259xs x\u00fcsusi \u0259m\u0259k \u015f\u0259raiti yarad\u0131lm\u0131\u015f istehsalatda, yaxud evd\u0259 m\u00fcxt\u0259lif n\u00f6v i\u015fl\u0259rd\u0259 i\u015fl\u0259y\u0259 bil\u0259r. Birinci d\u0259r\u0259c\u0259 \u0259lillik a\u015fa\u011f\u0131dak\u0131 hallarda t\u0259yin edilir:<\/p>\n\n\n\n

2.1.1. qan d\u00f6vran\u0131n\u0131n \u00fc\u00e7\u00fcnc\u00fc d\u0259r\u0259c\u0259li xroniki \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 (I01-I09, I11.0, I13.0-I13.2, I23-I23.8, I24-I24.8, I25.3-I25.5, I50-I50.9);<\/p>\n\n\n\n

2.1.2. talassemiya-homoziqot b\u00f6y\u00fck talassemiya, g\u00fccl\u00fc v\u0259 tez-tez t\u0259krar olunan hemolitik sindrom (D56-D56.9);<\/p>\n\n\n\n

2.1.3. \u00fc\u00e7\u00fcnc\u00fc d\u0259r\u0259c\u0259li a\u011fciy\u0259r-\u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 dekompensasiya m\u0259rh\u0259l\u0259si (I27.0-I27.9, I28.0-I28.8);<\/p>\n\n\n\n

2.1.4. xroniki b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131n\u0131n terminal m\u0259rh\u0259l\u0259si (N18.1-N18.9);<\/p>\n\n\n\n

2.1.5. xroniki qaraciy\u0259r \u00e7at\u0131\u015fmazl\u0131\u011f\u0131n\u0131n terminal m\u0259rh\u0259l\u0259si (K72.0-K72.9);<\/p>\n\n\n\n

2.1.6. \u00fcr\u0259k transplantasiyas\u0131ndan sonrak\u0131 v\u0259ziyy\u0259t (dig\u0259r orqan transplantasiyalar\u0131nda \u0259lillik d\u0259r\u0259c\u0259si transplant\u0131n funksional v\u0259ziyy\u0259tind\u0259n as\u0131l\u0131 olaraq t\u0259yin edilir) (Y83.0);<\/p>\n\n\n\n

2.1.7. inkurabel onkoloji x\u0259st\u0259likl\u0259r (C00-C97);<\/p>\n\n\n\n

2.1.8. \u0259traflar\u0131n h\u0259r\u0259k\u0259t funksiyas\u0131n\u0131n v\u0259 h\u0259r\u0259k\u0259t koordinasiyas\u0131n\u0131n k\u0259skin t\u0259zah\u00fcrl\u00fc pozulmas\u0131 (tetraplegiya, triplegiya, hemiplegiya, paraplegiya, tetraparez, triparez, n\u0259z\u0259r\u0259\u00e7arpanparaparez, ataksiya, intension titr\u0259m\u0259 il\u0259 hiperkinetik sindrom) v\u0259 ya total afaziya il\u0259 n\u0259tic\u0259l\u0259nmi\u015f sinir sisteminin m\u00fcxt\u0259lif x\u0259st\u0259likl\u0259ri-ba\u015f beynin insultu, ba\u015f beynin travmatik x\u0259st\u0259likl\u0259ri, u\u015faq serebral iflici, sinir sisteminin a\u011f\u0131r infeksion x\u0259st\u0259likl\u0259ri (I60-I66.9,G80-G80.9, S06.0-S06.9);<\/p>\n\n\n\n

2.1.9. h\u0259r iki g\u00f6z\u00fcn tam v\u0259 ya \u0259m\u0259li korlu\u011fu (yax\u015f\u0131 g\u00f6r\u0259n g\u00f6zd\u0259 g\u00f6rm\u0259 itiliyinin korreksiya il\u0259 0.04 v\u0259 ondan az olmas\u0131 v\u0259 ya g\u00f6rm\u0259 sah\u0259sinin 10 d\u0259r\u0259c\u0259y\u0259d\u0259k konsentrik daralmas\u0131) (H54-H54.9);<\/p>\n\n\n\n

2.1.10. iki \u0259traf\u0131n g\u00fcd\u00fcl\u00fc (S48.0-S48.9, S58, S68, S78, S88, S98);<\/p>\n\n\n\n

2.1.11. birinci barmaq da daxil olmaqla, h\u0259r iki \u0259lin \u00fc\u00e7 v\u0259 ya birinci barmaqs\u0131z d\u00f6rd barma\u011f\u0131n\u0131n olmamas\u0131, h\u0259min barmaqlar\u0131n k\u0259skin kontrakturas\u0131 v\u0259 ya daha yuxar\u0131dan amputasiya n\u0259tic\u0259sind\u0259 \u0259ll\u0259rin g\u00fcd\u00fcl\u00fc (S68, M16.0-M16.9);<\/p>\n\n\n\n

2.1.12. h\u0259r iki bud-\u00e7anaq oynaqlar\u0131n\u0131n ankilozu (M24.6);<\/p>\n\n\n\n

2.1.13. etiologiyas\u0131ndan as\u0131l\u0131 olmayaraq, d\u0259rin v\u0259 a\u011f\u0131r d\u0259r\u0259c\u0259li k\u0259ma\u011f\u0131ll\u0131l\u0131q, h\u0259m\u00e7inin anadang\u0259lm\u0259 idiotiya, yaxud k\u0259skin n\u0259z\u0259r\u0259\u00e7arpan inbesillik (\u0130Q-35-d\u0259n a\u015fa\u011f\u0131 olanlar) (F70-F79);<\/p>\n\n\n\n

2.1.14. davran\u0131\u015f pozulmaqla uzunm\u00fcdd\u0259tli (iki ild\u0259n \u00e7ox) t\u0259zah\u00fcr ed\u0259n psixotik hallar (F23.0-F23.9, F91-F92.9);<\/p>\n\n\n\n

2.1.15. \u015fizofreniya x\u0259st\u0259liyi n\u0259tic\u0259sind\u0259 ba\u015f ver\u0259n psixi q\u00fcsur hal\u0131 (F20-F20.9);<\/p>\n\n\n\n

2.1.16. \u0130\u0130V-infeksiyas\u0131n\u0131n IV(Q\u0130\u00c7S) m\u0259rh\u0259l\u0259si, terminal v\u0259ziyy\u0259t (B20-B24).<\/p>\n\n\n\n

2.2. \u0130kinci d\u0259r\u0259c\u0259 \u0259lillik — x\u0259st\u0259lik, travma v\u0259 ya anadang\u0259lm\u0259 q\u00fcsurlar n\u0259tic\u0259sind\u0259 orqanizmin h\u0259yat f\u0259aliyy\u0259tinin (t\u0259hsilalma, \u00fcnsiyy\u0259t, uy\u011funla\u015fma, \u00f6z davran\u0131\u015f\u0131na n\u0259zar\u0259tetm\u0259, h\u0259r\u0259k\u0259tetm\u0259, \u00f6z\u00fcn\u0259 xidm\u0259tetm\u0259, \u0259m\u0259k f\u0259aliyy\u0259ti) el\u0259 k\u0259skin m\u0259hdudla\u015fmas\u0131 v\u0259 ya \u0259m\u0259k f\u0259aliyy\u0259tinin m\u00fcmk\u00fcn olmamas\u0131 hallar\u0131nda t\u0259yin edilir ki, h\u0259min x\u0259st\u0259nin k\u0259nar \u015f\u0259xsin yard\u0131m v\u0259 ya qullu\u011funa ehtiyac\u0131 olmas\u0131n. \u0130kinci d\u0259r\u0259c\u0259 \u0259lillik a\u015fa\u011f\u0131dak\u0131 hallarda t\u0259yin edilir:<\/p>\n\n\n\n

2.2.1. \u00fcr\u0259k q\u00fcsurlar\u0131 v\u0259 ya miokardda ba\u015f vermi\u015f d\u0259rin d\u0259yi\u015fiklikl\u0259r n\u0259tic\u0259sind\u0259 qan d\u00f6vran\u0131n\u0131n davaml\u0131 olaraq ikinci d\u0259r\u0259c\u0259 \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 (I01-I09, I11.0, I13-I13.2, I20-I25, I30-I31.9, I33);<\/p>\n\n\n\n

2.2.2 a\u011f\u0131r formal\u0131 b\u0259dxass\u0259li qan x\u0259st\u0259likl\u0259ri (C80-C96.9);<\/p>\n\n\n\n

2.2.3. a\u011fciy\u0259rl\u0259rin xroniki, proqressiv gedi\u015fli fibrokavernoz v\u0259r\u0259mi, ikinci d\u0259r\u0259c\u0259 t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 (A15-A16.9,J96-J96.9);<\/p>\n\n\n\n

2.2.4. ild\u0259 az\u0131 d\u00f6rd d\u0259f\u0259 k\u0259skinl\u0259\u015fm\u0259 v\u0259 ikinci d\u0259r\u0259c\u0259 t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 m\u00fc\u015fayi\u0259t olunan t\u0259n\u0259ff\u00fcs sistemi orqanlar\u0131n\u0131n xroniki x\u0259st\u0259likl\u0259ri (J31-J32.9,J35-J37.1J41.0-J70.9,J84-J86.9,J91-J95.8);<\/p>\n\n\n\n

2.2.5. \u00fcmumi qidalanman\u0131n k\u0259skin n\u0259z\u0259r\u0259\u00e7arpan d\u0259r\u0259c\u0259d\u0259 z\u0259ifl\u0259m\u0259si il\u0259 m\u00fc\u015fahid\u0259 olunan, h\u0259zm sisteminin tez-tez residiv ver\u0259n (ild\u0259 az\u0131 4 d\u0259f\u0259) a\u011f\u0131r xroniki x\u0259st\u0259likl\u0259ri (\u00fcmumi qidalanman\u0131n z\u0259ifl\u0259m\u0259si \u0259sas\u0259n boy-\u00e7\u0259ki \u0259msal\u0131na v\u0259 qan azl\u0131\u011f\u0131n\u0131n s\u0259viyy\u0259sin\u0259 g\u00f6r\u0259 m\u00fc\u0259yy\u0259n edilir, h\u0259zm trakt\u0131n\u0131n m\u00fcxt\u0259lif s\u0259viyy\u0259l\u0259rind\u0259 bu g\u00f6st\u0259ricil\u0259r m\u00fcxt\u0259lif c\u00fcr d\u0259yi\u015fdiyind\u0259n \u00fcmumi qidalanman\u0131n z\u0259ifl\u0259m\u0259 d\u0259r\u0259c\u0259sini nozoloji vahidd\u0259n as\u0131l\u0131 olaraq ekspert t\u0259yin edir) (K20-K22.1, K25-K29.9, K31.0-K31.9, K50-K55.9, K58-K60.5, K62-K63.9, K65.8, K71-K77.0, K85-K86.9);<\/p>\n\n\n\n

2.2.6. ikinci v\u0259 \u00fc\u00e7\u00fcnc\u00fc d\u0259r\u0259c\u0259 b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 ild\u0259 az\u0131 d\u00f6rd d\u0259f\u0259 k\u0259skinl\u0259\u015fm\u0259 il\u0259 m\u00fc\u015fayi\u0259t olunan xroniki b\u00f6yr\u0259k x\u0259st\u0259likl\u0259ri (N03, N11.9, N13-N13.9, N14-N14.4, N18-N18.9);<\/p>\n\n\n\n

2.2.7. endokrin x\u0259st\u0259likl\u0259r n\u0259tic\u0259sind\u0259 h\u0259d\u0259f orqanlarda funksiya pozuntular\u0131na s\u0259b\u0259b olan patoloji d\u0259yi\u015fiklikl\u0259r (E00, E07-E07.9, E10, E12, E15-E16.1, E22.0-E22.1, E23.0-E23.2, E23.7, E24-24.9, E25.8, E26.9, E27.1-E27.9, E32-E32.8, E34-E34.1, E34-E35.8);<\/p>\n\n\n\n

2.2.8. etiologiyas\u0131ndan as\u0131l\u0131 olmayaraq, a\u015fa\u011f\u0131 \u0259traflar\u0131n parezi, \u00e7anaq orqanlar\u0131n\u0131n funksiyalar\u0131n\u0131n pozulmas\u0131 (G30-G32.9, G80-G80.9);<\/p>\n\n\n\n

2.2.9. qabar\u0131q yadda\u015f z\u0259ifliyi, idrak\u0131n enm\u0259si, emosional labillik, vestib\u00fclyar pozuntular, g\u00f6rm\u0259 pozuntular\u0131 v\u0259 ya piramid \u00e7at\u0131\u015fmazl\u0131q \u0259lam\u0259tl\u0259ri, k\u0259skin n\u0259z\u0259r\u0259\u00e7arpan vegetativ v\u0259 h\u0259r\u0259ki-koordinator funksiyan\u0131n pozuntular\u0131 il\u0259 m\u00fc\u015fayi\u0259t olunan ba\u015f beynin v\u0259 sinir sisteminin m\u00fcxt\u0259lif m\u0259n\u015f\u0259li x\u0259st\u0259likl\u0259ri (G00-G14, G20,G23-G23.9, G25-G26, G35-G37.8, G45-G46.8, G95-G95.9);<\/p>\n\n\n\n

2.2.10. h\u0259r iki g\u00f6zd\u0259 g\u00f6rm\u0259 itiliyinin korreksiya il\u0259 0,08 v\u0259 ondan az olmas\u0131 v\u0259 ya g\u00f6rm\u0259 sah\u0259sinin 20 d\u0259r\u0259c\u0259y\u0259d\u0259k konsentrik daralmas\u0131 (H40-H40.9, H47-H47.5, H52-H53.9);<\/p>\n\n\n\n

2.2.11. epilepsiya, tez- tez t\u0259krarlanan (ayda az\u0131 4 d\u0259f\u0259) tutmalarla v\u0259 ya \u015f\u0259xsiyy\u0259tin n\u0259z\u0259r\u0259\u00e7arpan d\u0259r\u0259c\u0259d\u0259 d\u0259yi\u015film\u0259si il\u0259 (G40-G41.9);<\/p>\n\n\n\n

2.2.12. h\u0259r iki a\u015fa\u011f\u0131 \u0259traf damarlar\u0131n\u0131n xroniki x\u0259st\u0259likl\u0259ri, II \u2013 III d\u0259r\u0259c\u0259li arterial v\u0259 ya venoz \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 — (I70.2, I73-I74, I74.3, I80-I80.3, I83.0-I83.9);<\/p>\n\n\n\n

2.2.13. \u0130\u0130V-infeksiyas\u0131n\u0131n III v\u0259 IV (Q\u0130\u00c7S) m\u0259rh\u0259l\u0259l\u0259ri — (B20-B24);<\/p>\n\n\n\n

2.2.14. lokalizasiyas\u0131ndan as\u0131l\u0131 olmayaraq, III — IV m\u0259rh\u0259l\u0259 b\u0259dxass\u0259li \u015fi\u015fl\u0259r- (C00-C97);<\/p>\n\n\n\n

2.2.15. xoralanma il\u0259 m\u00fc\u015fayi\u0259t olunan xroniki yay\u0131lm\u0131\u015f d\u0259ri x\u0259st\u0259likl\u0259ri.<\/p>\n\n\n\n

2.3. \u00dc\u00e7\u00fcnc\u00fc d\u0259r\u0259c\u0259 \u0259lillik — x\u0259st\u0259lik, travma v\u0259 ya anadang\u0259lm\u0259 q\u00fcsurlar n\u0259tic\u0259sind\u0259 orqanizmin h\u0259yat f\u0259aliyy\u0259tinin (\u00fcnsiyy\u0259t, sosial uy\u011funla\u015fma, h\u0259r\u0259k\u0259t, \u0259m\u0259k f\u0259aliyy\u0259ti) m\u0259hdudla\u015fmas\u0131 hallar\u0131nda t\u0259yin edilir. \u018fm\u0259k f\u0259aliyy\u0259tinin m\u0259hdudla\u015fmas\u0131 m\u0259fhumunda g\u00f6r\u00fcl\u0259c\u0259k i\u015fin h\u0259cmi il\u0259 b\u0259rab\u0259r, ixtisas\u0131n enm\u0259si, anatomik q\u00fcsur n\u0259tic\u0259sind\u0259 professional \u0259m\u0259yin \u00e7\u0259tinl\u0259\u015fm\u0259si d\u0259 n\u0259z\u0259rd\u0259 tutulur. \u00dc\u00e7\u00fcnc\u00fc d\u0259r\u0259c\u0259 \u0259lillik a\u015fa\u011f\u0131dak\u0131 hallarda t\u0259yin edilir:<\/p>\n\n\n\n

2.3.1. \u0259traflardan birinin yalan\u00e7\u0131 oyna\u011f\u0131 (M84.0-M84.4, M96.0);<\/p>\n\n\n\n

2.3.2. dirs\u0259k oyna\u011f\u0131n\u0131n funksional yarars\u0131z v\u0259ziyy\u0259td\u0259 (60 d\u0259r\u0259c\u0259d\u0259n az v\u0259 ya 150 d\u0259r\u0259c\u0259d\u0259n \u00e7ox) olmas\u0131, yaxud saidin tam supinasiya v\u0259 ya pronasiya hal\u0131nda qalmas\u0131, ankilozu v\u0259 ya k\u0259skin kontrakturas\u0131 (h\u0259r\u0259k\u0259tin h\u0259cminin 10 d\u0259r\u0259c\u0259d\u0259n art\u0131q olmamas\u0131) (M21.2,M24.5-M24.6,M25.6,M67.1,M99.0);<\/p>\n\n\n\n

2.3.3. \u0259lin v\u0259 ya p\u0259nc\u0259nin iflici, bir \u0259traf\u0131n n\u0259z\u0259r\u0259\u00e7arpan parezi (G83.0, G83.2);<\/p>\n\n\n\n

2.3.4. epilepsiya seyr\u0259k tutmalarla (ayda iki d\u0259f\u0259d\u0259n az olmamaqla) (G40-G40.9);<\/p>\n\n\n\n

2.3.5. astenik tipli q\u00fcsur v\u0259 ya qeyri-sabit remissiya hal\u0131nda olan \u015fizofreniya (F20-F20.9);<\/p>\n\n\n\n

2.3.6. a\u011f\u0131r formal\u0131 b\u0259dxass\u0259li qan x\u0259st\u0259likl\u0259ri, remissiya m\u0259rh\u0259l\u0259sind\u0259 (C80-C96.9);<\/p>\n\n\n\n

2.3.7. II m\u0259rh\u0259l\u0259 b\u0259dxass\u0259li \u015fi\u015fl\u0259r (C00-C97);<\/p>\n\n\n\n

2.3.8. \u0130\u0130V-infeksiyas\u0131n\u0131n I-II m\u0259rh\u0259l\u0259l\u0259ri (B20-B24);<\/p>\n\n\n\n

2.3.9. uzun m\u00fcdd\u0259t dekompensasiya (alt\u0131 aydan \u00e7ox) v\u0259ziyy\u0259tind\u0259 olan \u015f\u0259xsiyy\u0259t pozuntular\u0131 v\u0259 psixopatiyalar (F60.0-F62.9, F45-F45.9, F48-F48.9).<\/p>\n\n\n\n

2.4. Tibbi g\u00f6st\u0259ri\u015f olan a\u015fa\u011f\u0131dak\u0131 x\u00fcsusi hallarda ikinci d\u0259r\u0259c\u0259 \u0259lillik m\u00fcdd\u0259tsiz t\u0259yin edilir:<\/p>\n\n\n\n

2.4.1. \u00fcr\u0259k ritminin s\u00fcni t\u0259nziml\u0259yicisi qoyuldu\u011fu hallarda \u00fcr\u0259k q\u00fcsurlar\u0131 v\u0259 ya miokardda ba\u015f vermi\u015f d\u0259rin d\u0259yi\u015fiklikl\u0259r n\u0259tic\u0259sind\u0259 qan d\u00f6vran\u0131n\u0131n davaml\u0131 olaraq ikinci d\u0259r\u0259c\u0259 \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 (I01-I09,I11.0, I13.0-I13.2, I23-I23.8, I24-I24.8, I25.3-I25.5, I50-I50.9, Z95.0);<\/p>\n\n\n\n

2.4.2. nefrektomiya n\u0259tic\u0259sind\u0259 v\u0259 ya anadang\u0259lm\u0259 bir b\u00f6yr\u0259yin olmamas\u0131: ikinci d\u0259r\u0259c\u0259li xroniki b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 (N18-N18.9, Q60, Z90.5);<\/p>\n\n\n\n

2.4.3. \u015fizofreniya, paranoidpsixotik hal\u0131 (remissiya ba\u015f verm\u0259y\u0259n hal) (F20-F20.9);<\/p>\n\n\n\n

2.4.4. emosional-iradi pozuntular v\u0259 psixopatab\u0259nz\u0259r davran\u0131\u015fla m\u00fc\u015fayi\u0259t olunan imbesillik v\u0259 ya debillik \u0130Q=35-50 aras\u0131, o c\u00fcml\u0259d\u0259n orta d\u0259r\u0259c\u0259li k\u0259ma\u011f\u0131ll\u0131q(demensiya) (F60.0-F62.9, F45-F45.9, F48-F48.9, F70-F79);<\/p>\n\n\n\n

2.4.5. da\u011f\u0131n\u0131q skleroz (G35);<\/p>\n\n\n\n

2.4.6. bir budun g\u00fcd\u00fcl\u00fc (Z89.8);<\/p>\n\n\n\n

2.4.7. bir \u0259lin olmamas\u0131 (Q71.2, Z89.1);<\/p>\n\n\n\n

2.4.8. beyin madd\u0259sind\u0259 v\u0259 ya miokardda yad cismin olmas\u0131 — (Z95.0-Z95.8, T82.5);<\/p>\n\n\n\n

2.4.9. tez-tez m\u00fc\u015fahid\u0259 olunan daxili qanaxma hemoartrozla m\u00fc\u015fayi\u0259t olunan hemofiliya (D66);<\/p>\n\n\n\n

2.4.10. heteroziqot B talassemiya v\u0259 davaml\u0131 anemiya il\u0259 m\u00fc\u015fayi\u0259t olunan homoziqot talassemiya (D56.1).<\/p>\n\n\n\n

2.5. Tibbi g\u00f6st\u0259ri\u015f olan a\u015fa\u011f\u0131dak\u0131 x\u00fcsusi hallarda \u00fc\u00e7\u00fcnc\u00fc d\u0259r\u0259c\u0259 \u0259lillik m\u00fcdd\u0259tsiz t\u0259yin edilir:<\/p>\n\n\n\n

2.5.1. bir \u0259ld\u0259 \u00fc\u00e7 barma\u011f\u0131n olmamas\u0131, onlar\u0131n funksional yarars\u0131z v\u0259ziyy\u0259td\u0259 ankilozu v\u0259 ya k\u0259skin kontrakturas\u0131(Q71.3, Q74, M20.0, M24.5, Z89.0);<\/p>\n\n\n\n

2.5.2. birinci v\u0259 ikinci barmaqlar\u0131n m\u00fcvafiq daraq s\u00fcm\u00fckl\u0259ri il\u0259 birg\u0259 olmamas\u0131, h\u0259r iki \u0259ld\u0259 ba\u015f barmaqlar\u0131n v\u0259 ya dig\u0259r iki barma\u011f\u0131n olmamas\u0131 (Q71.3,);<\/p>\n\n\n\n

2.5.3. bir \u0259ld\u0259 1 barmaq istisna olmaqla d\u00f6rd barma\u011f\u0131n v\u0259 ya onlar\u0131n funksional yarars\u0131z v\u0259ziyy\u0259td\u0259 ankilozu v\u0259 ya k\u0259skin kontrakturas\u0131 (Q71.3, M24.6);<\/p>\n\n\n\n

2.5.4. bald\u0131r\u0131n g\u00fcd\u00fcl\u00fc, p\u0259nc\u0259nin Piroqov \u00fczr\u0259 v\u0259 ya \u015eopar oyna\u011f\u0131ndan amputasiyas\u0131, h\u0259r iki p\u0259nc\u0259nin \u015earp \u00fczr\u0259 (daraq s\u00fcm\u00fckl\u0259rinin ba\u015f\u0131 s\u0259viyy\u0259sind\u0259n) amputasiyas\u0131 Z89.8,Z97.1);<\/p>\n\n\n\n

2.5.5. topuq oyna\u011f\u0131n\u0131n ankilozu v\u0259 ya k\u0259skin kontrakturas\u0131 n\u0259tic\u0259sind\u0259 p\u0259nc\u0259nin q\u00fcsurlu v\u0259ziyy\u0259ti, a\u015fa\u011f\u0131 \u0259traf funksiyas\u0131n\u0131n pozulmas\u0131 il\u0259 (M21.3, M21.6, M24.6, Q72-Q72.7);<\/p>\n\n\n\n

2.5.6. h\u0259r iki topu\u011fun ankilozu v\u0259 ya k\u0259skin kontrakturas\u0131 (M24.5-M24.6);<\/p>\n\n\n\n

2.5.7. bud-\u00e7anaq oyna\u011f\u0131n\u0131n funksional yarars\u0131z v\u0259ziyy\u0259td\u0259 ankilozu v\u0259 ya k\u0259skin kontrakturas\u0131 (M16.1,M24.6);<\/p>\n\n\n\n

2.5.8. h\u0259r iki bud-\u00e7anaq oyna\u011f\u0131n\u0131n anadang\u0259lm\u0259 v\u0259 ya qazan\u0131lm\u0131\u015f \u00e7\u0131x\u0131\u011f\u0131 (Q65.0, M16.2-M16.9);<\/p>\n\n\n\n

2.5.9. bir bud-\u00e7anaq oyna\u011f\u0131n\u0131n anadang\u0259lm\u0259 v\u0259 ya qazan\u0131lm\u0131\u015f \u00e7\u0131x\u0131\u011f\u0131, a\u015fa\u011f\u0131 \u0259traf funksiyas\u0131n\u0131n n\u0259z\u0259r\u0259\u00e7arpan d\u0259r\u0259c\u0259d\u0259 pozuntusu (Q65.0, M16.3, M16.5);<\/p>\n\n\n\n

2.5.10. bir a\u015fa\u011f\u0131 \u0259traf\u0131n 7 sm q\u0131sa olmas\u0131 (M84.1, M96.0);<\/p>\n\n\n\n

2.5.11. diz v\u0259 ya bud-\u00e7anaq oynaqlar\u0131n\u0131n endoprotezi (M40-M41.3);<\/p>\n\n\n\n

2.5.12. \u00fc\u00e7\u00fcnc\u00fc-d\u00f6rd\u00fcnc\u00fc d\u0259r\u0259c\u0259 kifoskolioz, k\u0259skin funksiya pozuntusu (M40-M41.9);<\/p>\n\n\n\n

2.5.13. \u0259lin v\u0259 ya p\u0259nc\u0259nin iflici (G83.0-G83.3);<\/p>\n\n\n\n

2.5.14. bir g\u00f6z\u00fcn olmamas\u0131 v\u0259 ya \u0259m\u0259li korlu\u011fu (g\u00f6rm\u0259 itiliyinin korreksiya il\u0259 0,04 v\u0259 ondanaz olmas\u0131, yaxud g\u00f6rm\u0259 sah\u0259sinin 10 d\u0259r\u0259c\u0259y\u0259d\u0259k konsentrik daralmas\u0131) (H54.4);<\/p>\n\n\n\n

2.5.15. \u00e7\u0259n\u0259nin v\u0259 ya s\u0259rt dama\u011f\u0131n \u00e7eyn\u0259m\u0259ni protez t\u0259min etm\u0259y\u0259n q\u00fcsurlar\u0131 (K10.0-K10.9)<\/p>\n\n\n\n

2.5.16. hipofizarnanizm, osteoxondropatiya, osteoxondrodist-rofiya, boyun inki\u015fafdan k\u0259skin qalmas\u0131 il\u0259 (c\u0131rtdanboyluluq) (E23.0,E23.7);<\/p>\n\n\n\n

2.5.17. hemolitikkrizl\u0259rl\u0259 m\u00fc\u015fayi\u0259t olunan (ild\u0259 d\u00f6rd d\u0259f\u0259d\u0259n az olmamaqla) qan x\u0259st\u0259likl\u0259ri (D66-D68.1);<\/p>\n\n\n\n

2.5.18. subklinik \u0259lam\u0259tl\u0259rl\u0259 ged\u0259n hemofiliya (D66);<\/p>\n\n\n\n

2.5.19. subklinik \u0259lam\u0259tl\u0259rl\u0259 ged\u0259n talassemiya minor (D56.1);<\/p>\n\n\n\n

2.5.20. anadang\u0259lm\u0259 lal-karl\u0131q v\u0259 yah\u0259r iki qula\u011f\u0131n karl\u0131\u011f\u0131,3-4-c\u00fc d\u0259r\u0259c\u0259 a\u011f\u0131r e\u015fitm\u0259 (H90-90.8)<\/p>\n\n\n\n

2.5.21. k\u0259ll\u0259 s\u00fcm\u00fcy\u00fcn\u00fcn geni\u015f ( 3x1sm-d\u0259n art\u0131q ) q\u00fcsuru (S02-S02.1);<\/p>\n\n\n\n

2.5.22. nefrektomiya n\u0259tic\u0259sind\u0259 v\u0259 ya anadang\u0259lm\u0259 bir b\u00f6yr\u0259yin olmamas\u0131, birinci d\u0259r\u0259c\u0259li xroniki b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 (Q60, N18-N18.9);<\/p>\n\n\n\n

2.5.23. bir a\u011fciy\u0259rin olmamas\u0131 (Q33.3, Z90.2);<\/p>\n\n\n\n

2.5.24. g\u00f6z\u0259\u00e7arpan davran\u0131\u015f pozuntular\u0131 olan debillik (\u0130Q=50-70 aras\u0131) v\u0259 ya y\u00fcng\u00fcl d\u0259r\u0259c\u0259li k\u0259ma\u011f\u0131ll\u0131q (demensiya) (F70-F79);<\/p>\n\n\n\n

2.5.25. etiologiyas\u0131ndan as\u0131l\u0131 olmayaraq, \u015f\u0259xsiyy\u0259tin d\u0259yi\u015film\u0259si v\u0259 ya d\u0259rketm\u0259 qabiliyy\u0259tinin azalmas\u0131 (F06).<\/p>\n\n\n\n

3. U\u015faqlar\u0131n sa\u011flaml\u0131q imkanlar\u0131 m\u0259hdudlu\u011funun m\u00fc\u0259yy\u0259n olunmas\u0131 meyarlar\u0131<\/strong><\/p>\n\n\n\n

3.1. U\u015faqlar\u0131n sa\u011flaml\u0131q imkanlar\u0131n\u0131n m\u0259hdudlu\u011fu a\u015fa\u011f\u0131dak\u0131 hallarda m\u00fc\u0259yy\u0259n edilir:<\/p>\n\n\n\n

3.1.1. neyroinfeksiya, k\u0259ll\u0259-beyin travmas\u0131 (KBT) n\u0259tic\u0259sind\u0259 n\u0259z\u0259r\u0259\u00e7arpan h\u0259r\u0259ki, psixi v\u0259 nitq pozuntular\u0131 (G00-G04.9);<\/p>\n\n\n\n

3.1.2. davaml\u0131, n\u0259z\u0259r\u0259\u00e7arpan h\u0259r\u0259ki pozuntular (\u0259traflar\u0131n parezi, generaliz\u0259 olunmu\u015f hiperkinezl\u0259r, koordinasiya pozulmalar\u0131 v\u0259 s.) (G81-G83.9);<\/p>\n\n\n\n

3.1.3. davaml\u0131 nitq pozuntular\u0131: alaliya, afaziyan\u0131n kompensasiya olunmayan formas\u0131, a\u011f\u0131r formal\u0131 dizartriya (F80-F80.9,F98.5-F98.6);<\/p>\n\n\n\n

3.1.4. onur\u011fa beyninin z\u0259d\u0259l\u0259nm\u0259si n\u0259tic\u0259sind\u0259 \u00e7anaq orqanlar\u0131n\u0131n funksiya pozulmalar\u0131 (G95);<\/p>\n\n\n\n

3.1.5. epilepsiya v\u0259 davaml\u0131, terapevtik rezistent epilepsiyaya ox\u015far hallar (ayda 1 v\u0259 ya daha \u00e7ox b\u00f6y\u00fck tutmalarla) v\u0259 ya tez-tez t\u0259krarlanan (h\u0259ft\u0259d\u0259 2-3 d\u0259f\u0259) ki\u00e7ik v\u0259 ya q\u0131colmas\u0131z tutmalar (G40-G41.9);<\/p>\n\n\n\n

3.1.6. dayan\u0131ql\u0131 psixotik hallar (6 ay v\u0259 daha art\u0131q davam ed\u0259n hallar) (F00-F98);<\/p>\n\n\n\n

3.1.7. e\u015fitm\u0259, g\u00f6rm\u0259, nitq, dayaq-h\u0259r\u0259k\u0259t aparat\u0131n\u0131n v\u0259 dig\u0259r sistem v\u0259 ya orqanlar\u0131n n\u0259z\u0259r\u0259\u00e7arpanpozulmalar\u0131 il\u0259 v\u0259 ya davran\u0131\u015f\u0131n patoloji formas\u0131 il\u0259 m\u00fc\u015ft\u0259r\u0259k debillik d\u0259r\u0259c\u0259sind\u0259 a\u011f\u0131l z\u0259ifliyi, autizm (F70-F79,F80-F80.9,F84-F84.9,F98.4-F98.9);<\/p>\n\n\n\n

3.1.8. h\u0259r iki g\u00f6z\u00fcn g\u00f6rm\u0259 itiliyinin z\u0259ifl\u0259m\u0259si, yax\u015f\u0131 g\u00f6r\u0259n g\u00f6zd\u0259 g\u00f6rm\u0259 itiliyinin korreksiya il\u0259 0.2-d\u0259n a\u015fa\u011f\u0131 olmas\u0131 v\u0259 ya g\u00f6rm\u0259 sah\u0259sinin 25 d\u0259r\u0259c\u0259y\u0259d\u0259k konsentrik daralmas\u0131 (H53-H54.9);<\/p>\n\n\n\n

3.1.9. q\u0131rtlaq v\u0259 traxeyan\u0131n anadang\u0259lm\u0259 v\u0259 ya qazan\u0131lm\u0131\u015f x\u0259st\u0259likl\u0259ri n\u0259tic\u0259sind\u0259 s\u0259rb\u0259st t\u0259n\u0259ff\u00fcs\u00fcn traxeostomik borusuz m\u00fcmk\u00fcn olmamas\u0131 (Q31-Q32.1,Z90.8);<\/p>\n\n\n\n

3.1.10. a\u011f\u0131r gedi\u015fli bronxial astma (J45-J45.9);<\/p>\n\n\n\n

3.1.11. m\u0259d\u0259-ba\u011f\u0131rsaq trakt\u0131n\u0131n, qaraciy\u0259rin v\u0259 \u00f6d yollar\u0131n\u0131n x\u0259st\u0259liyi, yaxud inki\u015faf q\u00fcsurlar\u0131 n\u0259tic\u0259sind\u0259 h\u0259zmin v\u0259 ya qaraciy\u0259rin funksiyalar\u0131n\u0131n n\u0259z\u0259r\u0259\u00e7arpan, dayan\u0131ql\u0131 pozulmalar\u0131 (Q40.2-Q45, K25-K31.8, K50-55.9, K58-K59.2, K71.2-K72.9, K80-83.9);<\/p>\n\n\n\n

3.1.12. \u00fcr\u0259yin ritm pozulmalar\u0131 (o c\u00fcml\u0259d\u0259n kardiostimulyator implantasiyas\u0131 il\u0259) n\u0259tic\u0259sind\u0259 sinkopal v\u0259ziyy\u0259t, dur\u011funluq tipli II-III d\u0259r\u0259c\u0259li \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 ya xroniki n\u0259z\u0259r\u0259\u00e7arpan hipoksemiya il\u0259 f\u0259sadla\u015fm\u0131\u015f anadang\u0259lm\u0259 v\u0259 qazan\u0131lm\u0131\u015f x\u0259st\u0259likl\u0259ri (Q20-Q24.9, \u013001-\u013009.9, \u013047-\u013049.9, Z95-Z95.9);<\/p>\n\n\n\n

3.1.13. b\u00f6yr\u0259kl\u0259rin n\u0259z\u0259r\u0259\u00e7arpan dayan\u0131ql\u0131 funksiya pozulmalar\u0131, b\u00f6yr\u0259k toxumas\u0131nda patoloji prosesin y\u00fcks\u0259k f\u0259all\u0131q d\u0259r\u0259c\u0259si (N00-N16.8, N17-N19, N20-N29.8);<\/p>\n\n\n\n

3.1.14. davaml\u0131, II-III d\u0259r\u0259c\u0259li t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 ya k\u0259skin intoksikasiya il\u0259 m\u00fc\u015fayi\u0259t olunan a\u011fciy\u0259r v\u0259 d\u00f6\u015fdaxili limfa v\u0259zl\u0259rinin v\u0259r\u0259mi (A15-A16.9, A19, J96.0-J96.9);<\/p>\n\n\n\n

3.1.15. qan\u0131n anadang\u0259lm\u0259 v\u0259 irsi x\u0259st\u0259likl\u0259ri (ild\u0259 1 v\u0259 daha \u00e7ox krizl\u0259rl\u0259 v\u0259 hemoqlobinin 100 q\/l-d\u0259n a\u015fa\u011f\u0131 enm\u0259si il\u0259) (D51.0, D51.1, D55.0-D55.9, DD56-D59.9, D61.0, D64.0, D64.4, D64.8, D66, D67, D68.0-D68.9, D70-D72.9, D74.0);<\/p>\n\n\n\n

3.1.16. hemorragikvaskulit n\u0259tic\u0259sind\u0259 ba\u015f vermi\u015f, iki aydan \u00e7ox davam ed\u0259n v\u0259 h\u0259r il t\u0259krar olunan patoloji hallar (M31.8);<\/p>\n\n\n\n

3.1.17. d\u0259ri \u00f6rt\u00fcy\u00fcn\u00fcn v\u0259 ya selikli qi\u015fan\u0131n geni\u015fh\u0259cmli z\u0259d\u0259l\u0259nm\u0259l\u0259ri (xoralar\u0131, eritrodermiya, \u00e7ap\u0131qlar v\u0259 s.) n\u0259tic\u0259sind\u0259 \u00e7eyn\u0259m\u0259, udma, defekasiya funksiyalar\u0131n\u0131n pozulmalar\u0131na, sosial dezadaptasiya v\u0259 fiziki aktivliyin k\u0259skin m\u0259hdudla\u015fmas\u0131na s\u0259b\u0259b olan patoloji hallar (L00-L99);<\/p>\n\n\n\n

3.1.18. birl\u0259\u015fdirici toxuman\u0131n diffuz, y\u00fcks\u0259k f\u0259all\u0131q s\u0259viyy\u0259si il\u0259 ke\u00e7\u0259n, 3 aydan \u00e7ox davam ed\u0259n v\u0259 h\u0259r il t\u0259krarlanan x\u0259st\u0259likl\u0259ri n\u0259tic\u0259sind\u0259 ba\u015f vermi\u015f patoloji hallar (M31.5,M32.,M34.0-M34.1);<\/p>\n\n\n\n

3.1.19. m\u00fc\u0259yy\u0259n x\u0259st\u0259likl\u0259rin m\u00fcalic\u0259si m\u0259qs\u0259di il\u0259 g\u00fccl\u00fc t\u0259sir ed\u0259n d\u0259rman preparatlar\u0131n\u0131n uzunm\u00fcdd\u0259tli t\u0259tbiqi n\u0259tic\u0259sind\u0259 ba\u015f vermi\u015f, 3 aydan art\u0131q davam ed\u0259n v\u0259 terapevtik korreksiya t\u0259l\u0259b olunan patoloji hallar (madd\u0259l\u0259r m\u00fcbadil\u0259sinin pozuntusu, qan\u0131n formulunun d\u0259yi\u015film\u0259si v\u0259 s.) (D80-D89);<\/p>\n\n\n\n

3.1.20. b\u0259dxass\u0259li t\u00f6r\u0259m\u0259l\u0259r, c\u0259rrahi v\u0259 dig\u0259r n\u00f6v m\u00fcalic\u0259d\u0259n sonrak\u0131 hal (C00-C97,Z98.8);<\/p>\n\n\n\n

3.1.21. h\u0259yat f\u0259aliyy\u0259tinin qism\u0259n pozulmas\u0131 v\u0259 sosial dezadaptasiyaya s\u0259b\u0259b olmu\u015f, anadang\u0259lm\u0259 v\u0259 ya irsi x\u0259st\u0259lik v\u0259 sindromlar (Q00-Q99);<\/p>\n\n\n\n

3.1.22. c\u0259rrahi \u0259m\u0259liyyatdan sonra uzunm\u00fcdd\u0259tli sa\u011falma v\u0259 reabilitasiya m\u00fcalic\u0259si t\u0259l\u0259b olunan hallar (Z98.8, K91.1-K91.9, K92-K92.9);<\/p>\n\n\n\n

3.1.23. bir v\u0259 ya daha art\u0131q \u0259traf\u0131n n\u0259z\u0259r\u0259\u00e7arpan d\u0259rin parezi v\u0259 ya iflici, dayan\u0131ql\u0131 yay\u0131lm\u0131\u015f hiperkinezl\u0259r (ikili atetoz, xoreoatetoz tipli) n\u0259z\u0259r\u0259\u00e7arpan koordinasiya pozulmalar\u0131 \u2013 (R26.0-R26.8, R27.0-R 27.9);<\/p>\n\n\n\n

3.1.24. dayan\u0131ql\u0131, terapiya c\u0259h\u0259td\u0259n iki ild\u0259n \u00e7ox rezistent olan q\u0131colmalar (G40.0-G41.9);<\/p>\n\n\n\n

3.1.25. imbesillik v\u0259 idiotiya d\u0259r\u0259c\u0259sind\u0259 olan oliqofreniya v\u0259 ya dig\u0259r m\u0259n\u015f\u0259li a\u011f\u0131l z\u0259ifliyi, daun sindromu (F71-F72, F73,F79, Q90);<\/p>\n\n\n\n

3.1.26. anadang\u0259lm\u0259 lal-karl\u0131q, e\u015fitm\u0259 funksiyas\u0131n\u0131n olmamas\u0131 (III-IV d\u0259r\u0259c\u0259li neyrosensor a\u011f\u0131re\u015fitm\u0259) (Q16.0-Q16.9, H90-H90.5);<\/p>\n\n\n\n

3.1.27. g\u00f6rm\u0259 orqan\u0131n\u0131n ikit\u0259r\u0259fli, davaml\u0131, b\u0259rpaolunmaz, anadang\u0259lm\u0259 v\u0259 ya qazan\u0131lm\u0131\u015f x\u0259st\u0259likl\u0259ri (g\u00f6rm\u0259 itiliyinin yax\u015f\u0131 g\u00f6r\u0259n g\u00f6zd\u0259 korreksiya il\u0259 0.2-d\u0259n a\u015fa\u011f\u0131 olmas\u0131 v\u0259 ya g\u00f6rm\u0259 sah\u0259sinin 25 d\u0259r\u0259c\u0259y\u0259d\u0259k konsentrik daralmas\u0131), bir g\u00f6z\u00fcn olmamas\u0131 v\u0259 ya tam korlu\u011fu (H53.0-H53.9, H54.9,Z90.8, Q10-Q15.9);<\/p>\n\n\n\n

3.1.28. madd\u0259l\u0259r m\u00fcbadil\u0259sinin x\u00fcsusi p\u0259hriz t\u0259l\u0259b ed\u0259n anadang\u0259lm\u0259, irsi x\u0259st\u0259likl\u0259ri (K90.0, E70.0-E88.9);<\/p>\n\n\n\n

3.1.29. hidrosefaliyaya g\u00f6r\u0259 \u015funtlama \u0259m\u0259liyyat\u0131ndan sonrak\u0131 hal (Z98.8);<\/p>\n\n\n\n

3.1.30. bronx-a\u011fciy\u0259r sisteminin anadang\u0259lm\u0259 v\u0259 ya irsi x\u0259st\u0259likl\u0259ri (mukovissidoz, xroniki gedi\u015fli alveolitl\u0259r v\u0259 ya a\u011fciy\u0259rin dig\u0259r disseminasiyal\u0131 x\u0259st\u0259likl\u0259ri) (Q32.0-Q33.9, J40-J98.4);<\/p>\n\n\n\n

3.1.31. dayan\u0131ql\u0131 II-III d\u0259r\u0259c\u0259li t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 m\u00fc\u015fayi\u0259t olunan anadang\u0259lm\u0259 v\u0259 ya qazan\u0131lm\u0131\u015f xroniki a\u011fciy\u0259r-bronx x\u0259st\u0259likl\u0259ri, hormon as\u0131l\u0131l\u0131ql\u0131 bronxial astma (Q32.0-Q33.9, J40-J98.4);<\/p>\n\n\n\n

3.1.32. \u00fcr\u0259yin inkurabel x\u0259st\u0259likl\u0259ri, dur\u011funluq tipli II-III d\u0259r\u0259c\u0259li \u00fcr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 il\u0259 (\u013000-\u013009.9,\u013020-\u013052.8);<\/p>\n\n\n\n

3.1.33. anadang\u0259lm\u0259 v\u0259 qazan\u0131lm\u0131\u015f x\u0259st\u0259likl\u0259r n\u0259tic\u0259sind\u0259 qaraciy\u0259r funksiyas\u0131n\u0131n n\u0259z\u0259r\u0259\u00e7arpan, dayan\u0131ql\u0131, b\u0259rpa olunmaz pozulmalar\u0131 (K70-K77.8, Q44-Q44.7);<\/p>\n\n\n\n

3.1.34. xroniki b\u00f6yr\u0259k \u00e7at\u0131\u015fmazl\u0131\u011f\u0131, b\u0259dxass\u0259li hipertoniya, b\u00f6yr\u0259k m\u0259n\u015f\u0259li \u015f\u0259k\u0259rsiz diabet (N17-19, \u013010-\u013015, E23.2, N25.1);<\/p>\n\n\n\n

3.1.35. inkurabel b\u0259dxass\u0259li t\u00f6r\u0259m\u0259l\u0259r, \u00fczv\u00fcn funksiyas\u0131n\u0131 pozmu\u015f, c\u0259rrahi m\u00fcalic\u0259si m\u00fcmk\u00fcn olmayan xo\u015fxass\u0259li t\u00f6r\u0259m\u0259l\u0259r (C00-C97);<\/p>\n\n\n\n

3.1.36. m\u00fcalic\u0259si m\u00fcmk\u00fcn olmayan daimi sidik, n\u0259cis v\u0259 sidik t\u0259nas\u00fcl fistullar\u0131, sidik v\u0259 n\u0259cis saxlaman\u0131n pozulmalar\u0131 (N36.0, N82.1, K60.3, R15.R32);<\/p>\n\n\n\n

3.1.37. daxili orqanlar\u0131n (a\u011fciy\u0259r, qaraciy\u0259r, b\u00f6yr\u0259kl\u0259r, sidik kis\u0259si v\u0259 s.) \u00e7\u0131xar\u0131lmas\u0131, rezeksiyas\u0131 v\u0259 ya olmamas\u0131, h\u0259m\u00e7inin inki\u015fafdan qalmas\u0131 n\u0259tic\u0259sind\u0259 funksiyalar\u0131n dayan\u0131ql\u0131 pozulmas\u0131 il\u0259 n\u0259tic\u0259l\u0259nmi\u015f patoloji hallar (Q33.3, Q44.7, Q60.0-Q60.2, Q64.5, J96., J98, K72, N17-N19);<\/p>\n\n\n\n

3.1.38. anadang\u0259lm\u0259 q\u00fcsurlar (orqanlar\u0131n tam v\u0259 ya qism\u0259n aplaziyas\u0131), \u00fcz skeleti v\u0259 \u0259z\u0259l\u0259l\u0259rin qazan\u0131lm\u0131\u015f defekt v\u0259 deformasiyalar\u0131 n\u0259tic\u0259sind\u0259 t\u0259n\u0259ff\u00fcs, \u00e7eyn\u0259m\u0259, udma, nitq funksiyas\u0131n\u0131n pozulmas\u0131 (Q18, Q30.1, Q31.2, Q31.8, Q32.1, Q32.4, Q33.3, Q34.8, Q38-Q39.9, Q67.4, R06, R13, R47, R49, K07);<\/p>\n\n\n\n

3.1.39. dayaq-h\u0259r\u0259k\u0259t aparat\u0131 orqanlar\u0131n\u0131n n\u0259z\u0259r\u0259\u00e7arpan, dayan\u0131ql\u0131 b\u0259rpaolunmazpozulmalar\u0131 (G80.0-G80.9, A80, B91, Q05, Q06.2-Q06.4, Q65-Q66, Q67.5-Q68.8, Q71-Q74, Q76-Q79, M08, M41, S10-S39, R26, R27);<\/p>\n\n\n\n

3.1.40. bir \u0259traf\u0131n g\u00fcd\u00fcl\u00fc (T92.6, T93.6);<\/p>\n\n\n\n

3.1.41. birinci barmaq da daxil olmaqla \u0259lin \u00fc\u00e7 v\u0259 ya onsuz d\u00f6rd barma\u011f\u0131n\u0131n olmamas\u0131, h\u0259min barmaqlar\u0131n k\u0259skin kontrakturas\u0131 v\u0259 ya daha yuxar\u0131dan amputasiyas\u0131 n\u0259tic\u0259sind\u0259 \u0259lin g\u00fcd\u00fcl\u00fc (Q71.3,Z89.0, M20.0-M20.1, S68.0,T92.6);<\/p>\n\n\n\n

3.1.42. k\u0259ll\u0259 s\u00fcm\u00fcy\u00fcn\u00fcn geni\u015f\u00f6l\u00e7\u00fcl\u00fc s\u00fcm\u00fck defekti (Q67.4);<\/p>\n\n\n\n

3.1.43. ankilozlarla, kontrakturalarla, patoloji s\u0131n\u0131qlarla, skeletin deformasiyas\u0131 il\u0259 n\u0259tic\u0259l\u0259nmi\u015f skeletin sistem x\u0259st\u0259likl\u0259ri, dayaq-h\u0259r\u0259k\u0259t aparat\u0131n\u0131n inki\u015faf q\u00fcsurlar\u0131, habel\u0259 \u0259z\u0259l\u0259l\u0259rin patoloji d\u0259yi\u015fiklikl\u0259ri v\u0259 s\u00fcm\u00fck toxumas\u0131n\u0131n iri\u00f6l\u00e7\u00fcl\u00fc destruksiyalar\u0131 n\u0259tic\u0259sind\u0259 fiziki aktivliyin k\u0259skin m\u0259hdudla\u015fmas\u0131 v\u0259 ya h\u0259r\u0259k\u0259tin v\u0259 \u00f6z\u00fcn\u0259xidm\u0259tin m\u00fcmk\u00fcn olmamas\u0131 (M24.5-M24.6, M30-M36, M40-M43, M62, M80, M85-M89.9, Q65-Q66, Q67.5-Q67.8, Q68);<\/p>\n\n\n\n

3.1.44. onur\u011fan\u0131n v\u0259 d\u00f6\u015f q\u0259f\u0259sinin II d\u0259r\u0259c\u0259li t\u0259n\u0259ff\u00fcs \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 v\u0259 ya dayaq-h\u0259r\u0259k\u0259t aparat\u0131n\u0131n n\u0259z\u0259r\u0259\u00e7arpan funksiya pozuntusu il\u0259 m\u00fc\u015fayi\u0259t olunan III-IV d\u0259r\u0259c\u0259li deformasiyalar\u0131 (J96, R06-R06.8, R07.1, M40-M43);<\/p>\n\n\n\n

3.1.45. daxili sekresiya v\u0259zil\u0259rinin funksiya \u00e7at\u0131\u015fmazl\u0131\u011f\u0131. \u015e\u0259k\u0259rli diabet (insulind\u0259n as\u0131l\u0131 formas\u0131), \u015f\u0259k\u0259rsiz diabet, \u0130tsenko-Ku\u015finq x\u0259st\u0259liyi, b\u00f6yr\u0259k\u00fcst\u00fc v\u0259zin \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 (Addison x\u0259st\u0259liyi, total adrenoektomiyadan sonrak\u0131 hal, b\u00f6yr\u0259k\u00fcst\u00fc v\u0259zil\u0259rin qab\u0131\u011f\u0131n\u0131n anadang\u0259lm\u0259 disfunksiyas\u0131), hipofizar nanizm, qazan\u0131lm\u0131\u015f v\u0259 ya anadang\u0259lm\u0259 a\u011f\u0131r formal\u0131 hipotireoz, hipoparatireoz, IV d\u0259r\u0259c\u0259li piyl\u0259nm\u0259, a\u011f\u0131r formal\u0131 toksiki diffuzzob v\u0259 s. (E00-E04, E05, E10, E20-E21.3, E23.3, E24, E25, E27-E27.2, E66);<\/p>\n\n\n\n

3.1.46. leykoz, limfoqranulomatoz, histiositoz (D76.0,C81,C91-C95);<\/p>\n\n\n\n

3.1.47. qanyaranman\u0131n anadang\u0259lm\u0259 v\u0259 ya qazan\u0131lm\u0131\u015f hipoplastik v\u0259 aplastik v\u0259ziyy\u0259ti (hemoqlobinin 100 q\/l-d\u0259n a\u015fa\u011f\u0131 olmas\u0131, trombositl\u0259rin 1 kub\/mm-d\u0259 100.000-d\u0259n a\u015fa\u011f\u0131 olmas\u0131, leykositl\u0259rin 1 kub\/mm-d\u0259 4000-d\u0259n az olmas\u0131) (D60-D61);<\/p>\n\n\n\n

3.1.48. koaqulopatiya v\u0259 trombositopatiyan\u0131n a\u011f\u0131r formalar\u0131, trombositopenikpurpura, ard\u0131c\u0131l residivli gedi\u015f, a\u011f\u0131r hemorrogikkrizl\u0259rl\u0259 (qanda 1 kub\/mm-d\u0259 trombositl\u0259rin 50000-d\u0259n az olmas\u0131) (D65, D69.1-D69.3, D69.9);<\/p>\n\n\n\n

3.1.49. talassemiya (D56-D56.9);<\/p>\n\n\n\n

3.1.50. anadang\u0259lm\u0259 immun\u00e7at\u0131\u015fmazl\u0131\u011f\u0131 (D80-D89);<\/p>\n\n\n\n

3.1.51. a\u011f\u0131r kombin\u0259 olunmu\u015f immun\u00e7at\u0131\u015fmazl\u0131\u011f\u0131, aqammaqlobulinemiya, hipoqammaqlobulinemiya, septik qranulematoz, limfa v\u0259zil\u0259rinin a\u011fciy\u0259rl\u0259rin, qaraciy\u0259rin v\u0259 ba\u015fqa orqanlar\u0131n residivli bakterial yoluxmalar\u0131 (B20-B24);<\/p>\n\n\n\n

3.1.52. hiperimmunoqlobulinemiya \u2013 E sindromunun d\u0259rialt\u0131 toxuman\u0131n, a\u011fciy\u0259rl\u0259rin, qaraciy\u0259rin v\u0259 ba\u015fqa orqanlar\u0131n \u201csoyuq absesl\u0259ri\u201d il\u0259 m\u00fc\u015fayi\u0259t olunmas\u0131, immunoqlobulin E-nin qan\u0131n z\u0259rdab\u0131nda 1000 KED\/l-d\u0259n y\u00fcks\u0259k olmas\u0131;<\/p>\n\n\n\n

3.1.53. qazan\u0131lm\u0131\u015f immun\u00e7at\u0131\u015fmazl\u0131\u011f\u0131, klinik t\u0259zah\u00fcrl\u0259rl\u0259 (B20-B24).<\/p>\n\n\n\n

4. \u018flilliyin v\u0259 sa\u011flaml\u0131q imkanlar\u0131n\u0131n m\u0259hdudlu\u011funun m\u00fc\u0259yy\u0259n olunmas\u0131 m\u00fcdd\u0259tl\u0259ri<\/strong><\/p>\n\n\n\n

4.1. Birinci d\u0259r\u0259c\u0259 \u0259lillik v\u0259 tibbi g\u00f6st\u0259ri\u015folan x\u00fcsusi hallarda ikinci v\u0259 \u00fc\u00e7\u00fcnc\u00fc d\u0259r\u0259c\u0259 \u0259lillik m\u00fcdd\u0259tsiz m\u00fc\u0259yy\u0259n edilir.<\/p>\n\n\n\n

4.2. \u0130kinci v\u0259 \u00fc\u00e7\u00fcnc\u00fc d\u0259r\u0259c\u0259 \u0259lillik 5 (be\u015f) il m\u00fcdd\u0259tin\u0259 m\u00fc\u0259yy\u0259n edilir.\u0130kinci d\u0259r\u0259c\u0259 \u0259lillik fasil\u0259siz olaraq 10 (on) il, \u00fc\u00e7\u00fcnc\u00fc d\u0259r\u0259c\u0259 \u0259lillik fasil\u0259siz olaraq 15 (on be\u015f) il t\u0259yin olundu\u011fu halda \u0259lillik m\u00fcdd\u0259tsiz m\u00fc\u0259yy\u0259n edilir.<\/p>\n\n\n\n

4.3. \u018flillik d\u0259r\u0259c\u0259sind\u0259n as\u0131l\u0131 olmayaraq Az\u0259rbaycan Respublikas\u0131n\u0131n \u201c\u018fm\u0259k pensiyalar\u0131 haqq\u0131nda\u201d v\u0259 \u201cSosial m\u00fcavin\u0259tl\u0259r haqq\u0131nda\u201d qanunlar\u0131 il\u0259 m\u00fc\u0259yy\u0259n edilmi\u015f ya\u015fa g\u00f6r\u0259 \u0259m\u0259k pensiyas\u0131 v\u0259 yaxud sosial m\u00fcavin\u0259t almaq h\u00fcququ ver\u0259n ya\u015f h\u0259ddin\u0259 \u00e7atan \u015f\u0259xsl\u0259r\u0259 \u0259lillik m\u00fcdd\u0259t g\u00f6st\u0259rilm\u0259d\u0259n t\u0259yin edilir.<\/p>\n\n\n\n

4.4. Bu \u018fsasnam\u0259nin 3.1.1. \u2013 3.1.22-ci b\u0259ndl\u0259rind\u0259 g\u00f6st\u0259ril\u0259n hallarda 18 ya\u015fad\u0259k u\u015faqlar\u0131n sa\u011flaml\u0131q imkanlar\u0131n\u0131n m\u0259hdudlu\u011fu 18 ya\u015f\u0131ndan yuxar\u0131 olmamaqla 3 (\u00fc\u00e7) il m\u00fcdd\u0259tin\u0259, qalan hallarda is\u0259 18 ya\u015f\u0131nad\u0259k m\u00fc\u0259yy\u0259n olunur. 18 ya\u015f\u0131n\u0131n tamam olmas\u0131na 6 (alt\u0131) ay v\u0259 ondan daha az qalan u\u015faqlar\u0131n sa\u011flaml\u0131q imkanlar\u0131n\u0131n m\u0259hdudlu\u011fu 18 ya\u015f\u0131nad\u0259k m\u00fc\u0259yy\u0259n edilir.<\/p>\n\n\n\n

5. \u018flill\u0259r\u0259 v\u0259 sa\u011flaml\u0131q imkanlar\u0131 m\u0259hdud u\u015faqlara texniki v\u0259 dig\u0259r reabilitasiya vasit\u0259l\u0259ri verilm\u0259sin\u0259 tibbi g\u00f6st\u0259ri\u015fl\u0259r<\/strong><\/p>\n\n\n\n

5.1. Texniki reabilitasiya vasit\u0259l\u0259rinin (\u0259traflar\u0131n v\u0259 ya duy\u011fu orqanlar\u0131n\u0131n pozulmu\u015f funksiyalar\u0131n\u0131 \u0259v\u0259z etm\u0259k \u00fc\u00e7\u00fcn t\u0259tbiq olunan x\u00fcsusi avadanl\u0131q, cihazlar v\u0259 t\u0259rtibatlar) verilm\u0259si a\u015fa\u011f\u0131dak\u0131 hallarda t\u00f6vsiy\u0259 edilir:<\/p>\n\n\n\n

5.1.1. n\u0259z\u0259r\u0259 \u00e7arpan monoparez, hemiparez, paraparez, triparez (G81-G81.9, G82-G82.9,G83-G83.2);<\/p>\n\n\n\n

5.1.2. n\u0259z\u0259r\u0259\u00e7arpan ataksiya (R57.0);<\/p>\n\n\n\n

5.1.3. daimi olaraq sidiyi v\u0259 ya n\u0259cisi saxlaya bilm\u0259m\u0259k, o c\u00fcml\u0259d\u0259n sidik v\u0259 ya n\u0259cis fistulu (R32-R35, N32.1-N32.2, K60.3, K63.2);<\/p>\n\n\n\n

5.1.4. karl\u0131q (H83.3, H83.8-H83.9, H90-H90.8,H91-H91.9);<\/p>\n\n\n\n

5.1.5. d\u00f6rd barma\u011f\u0131n olmamas\u0131 v\u0259 ya \u0259lin daha yuxar\u0131dan amputasiya n\u0259tic\u0259sind\u0259 g\u00fcd\u00fcl\u00fc (S68.4, Z89.3);<\/p>\n\n\n\n

5.1.6. \u0259traflarda oynaqlar\u0131n n\u0259z\u0259r\u0259\u00e7arpan kontrakturas\u0131 (M24.5);<\/p>\n\n\n\n

5.1.7. bazu, dirs\u0259k, diz oynaqlar\u0131n\u0131n laxlamas\u0131 (M35.7);<\/p>\n\n\n\n

5.1.8. \u015farp \u00fczr\u0259 v\u0259 ya aya\u011f\u0131n daha yuxar\u0131dan amputasiya n\u0259tic\u0259sind\u0259 g\u00fcd\u00fcl\u00fc (S98-S98.4, Z89.6);<\/p>\n\n\n\n

5.1.9. h\u0259r iki g\u00f6z\u00fcn g\u00f6rm\u0259 itiliyinin korreksiya il\u0259 0.1 d\u0259r\u0259c\u0259y\u0259d\u0259k olmas\u0131 v\u0259 ya g\u00f6rm\u0259 sah\u0259sinin 20 d\u0259r\u0259c\u0259y\u0259d\u0259k konsentrik daralmas\u0131 (H53-H53.9);<\/p>\n\n\n\n

5.2. h\u0259r\u0259k\u0259ti t\u0259min ed\u0259n vasit\u0259l\u0259r:<\/p>\n\n\n\n

5.2.1. kreslo-araba (otaqda h\u0259r\u0259k\u0259t \u00fc\u00e7\u00fcn) a\u015fa\u011f\u0131dak\u0131 hallarda t\u00f6vsiy\u0259 edilir:<\/p>\n\n\n\n

5.2.1.1. \u00fcr\u0259k-qan d\u00f6vran\u0131n\u0131n \u00fc\u00e7\u00fcnc\u00fc d\u0259r\u0259c\u0259li xroniki \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 (\u013050-\u013050.9);<\/p>\n\n\n\n

5.2.1.2. \u00fc\u00e7\u00fcnc\u00fc d\u0259r\u0259c\u0259li a\u011fciy\u0259r-\u00fcr\u0259k dekompensasiya m\u0259rh\u0259l\u0259sind\u0259 (J98.8);<\/p>\n\n\n\n

5.2.1.3. hemiplegiya, n\u0259z\u0259r\u0259\u00e7arpanhemiparez, a\u015fa\u011f\u0131 paraplegiya, n\u0259z\u0259r\u0259\u00e7arpan a\u015fa\u011f\u0131 paraparez, triplegiya, n\u0259z\u0259r\u0259\u00e7arpantriparez, n\u0259z\u0259r\u0259\u00e7arpantetraparez (G81-G81.9, G82-G82.9,G83-G83.2);<\/p>\n\n\n\n

5.2.1.4. tetraplegiya k\u0259skin n\u0259z\u0259r\u0259\u00e7arpan ataksiya, hiperkinetik, amiostatik sindrom, tetraplegiya (G82.4-G82.5, F90, E83.0);<\/p>\n\n\n\n

5.2.1.5. h\u0259r iki bald\u0131r\u0131n g\u00fcd\u00fcl\u00fc v\u0259 ya amputasiyalar\u0131n daha y\u00fcks\u0259k s\u0259viyy\u0259si (S88-Z89.7);<\/p>\n\n\n\n

5.2.1.6. bir bald\u0131r\u0131n g\u00fcd\u00fcl\u00fc v\u0259 dig\u0259r a\u015fa\u011f\u0131 \u0259traf\u0131n funksional yarars\u0131z v\u0259ziyy\u0259td\u0259 olmas\u0131 (S88-Z89.7);<\/p>\n\n\n\n

5.2.2. velo-araba (\u00e7\u00f6ld\u0259 g\u0259zm\u0259k \u00fc\u00e7\u00fcn) 3.2.1.3-c\u00fc, 3.2.1.5-ci v\u0259 3.2.1.6-c\u0131 yar\u0131mb\u0259ndl\u0259rd\u0259 n\u0259z\u0259rd\u0259 tutulmu\u015f hallarda verilir;<\/p>\n\n\n\n

5.2.3. avtomobill\u0259r a\u015fa\u011f\u0131dak\u0131 hallarda verilir:<\/p>\n\n\n\n

5.2.3.1. ikinci-B d\u0259r\u0259c\u0259li xroniki qan d\u00f6vran\u0131 \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 (\u013099);<\/p>\n\n\n\n

5.2.3.2. ikinci d\u0259r\u0259c\u0259li a\u011fciy\u0259r \u00e7at\u0131\u015fmazl\u0131\u011f\u0131 (J96-J96.9);<\/p>\n\n\n\n

5.2.3.3. bir a\u015fa\u011f\u0131 \u0259traf\u0131n iflici v\u0259 ya n\u0259z\u0259r\u0259\u00e7arpan parezi (G92.9);<\/p>\n\n\n\n

5.2.3.4. hemiplegiya, n\u0259z\u0259r\u0259\u00e7arpan hemiparez (G81-G81.9);<\/p>\n\n\n\n

5.2.3.5. n\u0259z\u0259r\u0259\u00e7arpan ataksiya, hiperkinetik, amiostatik sindrom (R27.0,F90,E83.0);<\/p>\n\n\n\n

5.2.3.6. h\u0259r iki a\u015fa\u011f\u0131 \u0259traf\u0131n xroniki tromboobliterasiyaedici x\u0259st\u0259likl\u0259ri ikinci d\u0259r\u0259c\u0259 arterial \u00e7at\u0131\u015fmazl\u0131\u011f\u0131;<\/p>\n\n\n\n

5.2.3.7. a\u015fa\u011f\u0131 \u0259traflar\u0131n n\u0259z\u0259r\u0259\u00e7arpan trofik pozuntular\u0131 (h\u0259r iki a\u015fa\u011f\u0131 \u0259traf v\u0259 \u00e7anaq qur\u015fa\u011f\u0131 \u0259z\u0259l\u0259l\u0259rinin m\u00fcxt\u0259lif etiologiyal\u0131 atrofiyalar\u0131);<\/p>\n\n\n\n

5.2.3.8. a\u015fa\u011f\u0131 \u0259traf venalar\u0131n\u0131n x\u0259st\u0259likl\u0259ri, bir a\u015fa\u011f\u0131 \u0259trafda \u00fc\u00e7\u00fcnc\u00fc v\u0259 ya h\u0259r iki a\u015fa\u011f\u0131 \u0259trafda ikinci-\u00fc\u00e7\u00fcnc\u00fc d\u0259r\u0259c\u0259 venoz \u00e7at\u0131\u015fmazl\u0131qlar\u0131 (\u013080.3);<\/p>\n\n\n\n

5.2.3.9. h\u0259r iki a\u015fa\u011f\u0131 \u0259traf\u0131n fillik x\u0259st\u0259liyi (\u013089.0);<\/p>\n\n\n\n

5.2.3.10. h\u0259r iki \u0259lin g\u00fcd\u00fcl\u00fc (S68.0-S68.9, Z89.1);<\/p>\n\n\n\n

5.2.3.11. h\u0259r iki topu\u011fun ankilozu v\u0259 ya k\u0259skin kontrakturas\u0131 (h\u0259r\u0259k\u0259tin h\u0259cminin 5 d\u0259r\u0259c\u0259y\u0259d\u0259k m\u0259hdudla\u015fmas\u0131) (M24.6);<\/p>\n\n\n\n

5.2.3.12. h\u0259r iki p\u0259nc\u0259nin \u015earp \u00fczr\u0259 g\u00fcd\u00fcl\u00fc (ayaq dara\u011f\u0131 s\u00fcm\u00fck ba\u015fl\u0131qlar\u0131n\u0131n amputasiyas\u0131) v\u0259 ya h\u0259r iki a\u015fa\u011f\u0131 \u0259traf\u0131n y\u00fcks\u0259k s\u0259viyy\u0259d\u0259 g\u00fcd\u00fcl\u00fc \u2013 (S98-S98.4);<\/p>\n\n\n\n

5.2.3.13. bald\u0131r\u0131n g\u00fcd\u00fcl\u00fc (S88, Z89.7);<\/p>\n\n\n\n

5.2.3.14. bud-\u00e7anaq oynaqlar\u0131n\u0131n, \u0259traflar\u0131n funksiyas\u0131n\u0131n n\u0259z\u0259r\u0259\u00e7arpan d\u0259r\u0259c\u0259d\u0259 pozulmas\u0131 il\u0259 m\u00fc\u015fayi\u0259t edil\u0259n, anadang\u0259lm\u0259 v\u0259 ya qazan\u0131lm\u0131\u015f \u00e7\u0131x\u0131\u011f\u0131 (Q65-Q65.9, S73-S73.0);<\/p>\n\n\n\n

5.2.3.15. bud-\u00e7anaq v\u0259 ya diz oyna\u011f\u0131n\u0131n laxlamas\u0131 (M23.5);<\/p>\n\n\n\n

5.2.3.16. bud-\u00e7anaq oyna\u011f\u0131n\u0131n ankilozu v\u0259 ya k\u0259skin \u00e7arpan kontrakturas\u0131 (h\u0259r\u0259k\u0259tl\u0259rin h\u0259cmi 10 d\u0259r\u0259c\u0259y\u0259d\u0259k olduqda) (M24.5-M24.6);<\/p>\n\n\n\n

5.2.3.17. diz oyna\u011f\u0131n\u0131n ankilozu v\u0259 ya funksional \u0259lveri\u015fsiz v\u0259ziyy\u0259td\u0259 (150 d\u0259r\u0259c\u0259d\u0259n az v\u0259 170 d\u0259r\u0259c\u0259d\u0259n art\u0131q bucaq alt\u0131nda) k\u0259skin kontrakturas\u0131 (M24.5-M24.6);<\/p>\n\n\n\n

5.2.3.18. topuq oyna\u011f\u0131n\u0131n k\u0259skin n\u0259z\u0259r\u0259\u00e7arpankontrakturas\u0131 n\u0259tic\u0259sind\u0259 p\u0259nc\u0259nin q\u00fcsurlu v\u0259ziyy\u0259ti (T93.2-T93.3,M21.0-M21.6);<\/p>\n\n\n\n

5.2.3.19. h\u0259r iki bud v\u0259 ya bald\u0131r s\u00fcm\u00fckl\u0259rinin \u0259yri biti\u015fmi\u015f s\u0131n\u0131\u011f\u0131 n\u0259tic\u0259sind\u0259 onlar\u0131n 170 d\u0259r\u0259c\u0259d\u0259n az bucaq alt\u0131nda deformasiyas\u0131 (T93.2,M24.5);<\/p>\n\n\n\n

5.2.3.20. bir a\u015fa\u011f\u0131 \u0259traf v\u0259 ya ancaq qur\u015faq s\u00fcm\u00fckl\u0259rinin xroniki osteomieliti (2 ild\u0259n art\u0131q gedi\u015fli fistula v\u0259 ya sekvestrli bo\u015fluqlar\u0131n olmas\u0131 il\u0259) (M86.3);<\/p>\n\n\n\n

5.2.3.21. budda yalan\u00e7\u0131 oynaq, yaxud iri s\u00fcm\u00fck q\u00fcsuru olmas\u0131 (s\u00fcm\u00fcy\u00fcn \u00e7evr\u0259sinin yar\u0131s\u0131ndan art\u0131\u011f\u0131 da\u011f\u0131lmaqla) budun v\u0259 ya bald\u0131r\u0131n h\u0259r iki s\u00fcm\u00fcy\u00fcn\u00fcn yalan\u00e7\u0131 oyna\u011f\u0131 v\u0259 ya s\u00fcm\u00fck q\u00fcsuru, yaxud qam\u0131\u015f s\u00fcm\u00fcy\u00fcn\u00fcn incik s\u00fcm\u00fcy\u00fcnd\u0259 170 d\u0259r\u0259c\u0259d\u0259n ki\u00e7ik bucaq alt\u0131nda deformasiya olmaqla yalan\u00e7\u0131 oyna\u011f\u0131 v\u0259 ya s\u00fcm\u00fck q\u00fcsuru;<\/p>\n\n\n\n

5.2.3.22. bud-\u00e7anaq oyna\u011f\u0131n\u0131n endoprotezi (Z96.6,T84-84.9);<\/p>\n\n\n\n

5.2.3.23. h\u0259r iki diz oynaqlar\u0131n\u0131n endoprotezi (Z96.6);<\/p>\n\n\n\n

5.2.3.24. bir a\u015fa\u011f\u0131 \u0259traf\u0131n 10 sm q\u0131sa olmas\u0131 (Q72.4-Q72.9,T13.0-13.9);<\/p>\n\n\n\n

5.2.3.25. bald\u0131rda 20 kv.sm p\u0259nc\u0259nin \u00fcst s\u0259thind\u0259 10 kv.sm v\u0259 p\u0259nc\u0259nin alt s\u0259thind\u0259 \u0259n az\u0131 2 kv.sm \u00f6l\u00e7\u00fcl\u00fc uzun m\u00fcdd\u0259t (6 aydan art\u0131q) sa\u011falmayan xora, yaxud travmadan sonrak\u0131 trofik pozuntular (T93.0-T93.9);<\/p>\n\n\n\n

5.2.3.26. onur\u011fan\u0131n ayaq \u00fcst\u0259 dayanma\u011f\u0131 v\u0259 h\u0259r\u0259k\u0259ti xeyli \u00e7\u0259tinl\u0259\u015fdir\u0259n x\u0259st\u0259likl\u0259ri, deformasiyas\u0131, onur\u011fa funksiyas\u0131n\u0131n k\u0259skin n\u0259z\u0259r\u0259\u00e7arpan pozulmas\u0131 il\u0259 m\u00fc\u015fayi\u0259t olunan \u00fc\u00e7\u00fcnc\u00fc-d\u00f6rd\u00fcnc\u00fc d\u0259r\u0259c\u0259li \u0259yilm\u0259l\u0259ri;<\/p>\n\n\n\n

5.2.3.27. ankilozla\u015fd\u0131ranspondiloartrit (Bexterev x\u0259st\u0259liyi) bud-\u00e7anaq oynaqlar\u0131n\u0131n n\u0259z\u0259r\u0259\u00e7arpankontrakturas\u0131 il\u0259 (M45)<\/p>\n\n\n\n

5.2.3.28. m\u00fcharib\u0259 \u0259lill\u0259rinin h\u0259r iki g\u00f6z\u00fcn\u00fcn g\u00f6rm\u0259 itiliyi 0.04-d\u0259n a\u015fa\u011f\u0131 v\u0259 ya g\u00f6rm\u0259 sah\u0259si 10 d\u0259r\u0259c\u0259d\u0259n a\u015fa\u011f\u0131 olduqda (H53.0-H54.9);<\/p>\n\n\n\n

5.2.3.29. proqraml\u0131 hemodializ (Z99.2,Z49.0-Z49.1).<\/p>\n\n\n\n

6. Ke\u00e7id m\u00fcdd\u0259alar<\/strong><\/p>\n\n\n\n

6.1. Bu \u018fsasnam\u0259nin t\u0259sdiq edildiyi g\u00fcn\u0259d\u0259k \u0259lilliyi m\u00fc\u0259yy\u0259n edilmi\u015f v\u0259 h\u0259min g\u00fcn\u0259d\u0259k \u0259lillik m\u00fcdd\u0259ti ba\u015fa \u00e7atmam\u0131\u015f ikinci v\u0259 \u00fc\u00e7\u00fcnc\u00fc d\u0259r\u0259c\u0259 \u0259lilliyi olan \u015f\u0259xsl\u0259rin \u0259lillik m\u00fcdd\u0259ti TSERAS t\u0259r\u0259find\u0259n 5 (be\u015f) il m\u00fcdd\u0259tin\u0259 uzad\u0131l\u0131r.<\/p>\n\n\n\n

6.2. Bu \u018fsasnam\u0259nin t\u0259sdiq edildiyi g\u00fcn\u0259d\u0259k \u0259lilliyi m\u00fc\u0259yy\u0259n edilmi\u015f v\u0259 \u0259lillik m\u00fcdd\u0259ti ba\u015fa \u00e7atmam\u0131\u015f birinci d\u0259r\u0259c\u0259 \u0259lilliyi olan \u015f\u0259xsl\u0259rin \u0259lillik m\u00fcdd\u0259ti ba\u015fa \u00e7atd\u0131qdan sonra TSERAS t\u0259r\u0259find\u0259n m\u00fcdd\u0259tsiz m\u00fc\u0259yy\u0259n edilir.<\/p>\n\n\n\n

6.3. Bu \u018fsasnam\u0259nin 3.1.1- 3.1.22-ci yar\u0131mb\u0259ndl\u0259rind\u0259 g\u00f6st\u0259ril\u0259n s\u0259b\u0259bl\u0259rd\u0259n sa\u011flaml\u0131q imkanlar\u0131n\u0131n m\u0259hdudlu\u011fu m\u00fc\u0259yy\u0259n edilmi\u015f v\u0259 bu \u018fsasnam\u0259nin t\u0259sdiq edildiyi g\u00fcn\u0259d\u0259k sa\u011flaml\u0131q imkanlar\u0131n\u0131n m\u0259hdudlu\u011fu m\u00fcdd\u0259ti ba\u015fa \u00e7atmam\u0131\u015f 18 ya\u015fad\u0259k u\u015faqlar\u0131n sa\u011flaml\u0131q imkanlar\u0131n\u0131n m\u0259hdudlu\u011fu TSERAS t\u0259r\u0259find\u0259n, 18 ya\u015f\u0131ndan yuxar\u0131 olmamaqla 3 (\u00fc\u00e7) il m\u00fcdd\u0259tin\u0259 uzad\u0131l\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":"

Az\u0259rbaycan Respublikas\u0131 Nazirl\u0259rKabinetinin 2015-ci il 30 dekabr tarixli 413 n\u00f6mr\u0259li q\u0259rar\u0131 il\u0259 t\u0259sdiq edilmi\u015fdir 1. \u00dcmumi…<\/p>\n","protected":false},"author":3,"featured_media":8922,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-8921","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sosial"],"featured_image_urls":{"full":["https:\/\/veteran.az\/wp-content\/uploads\/2021\/03\/95016347_984048718677018_8866687943658438656_n.jpg",960,834,false],"thumbnail":["https:\/\/veteran.az\/wp-content\/uploads\/2021\/03\/95016347_984048718677018_8866687943658438656_n-150x150.jpg",150,150,true],"medium":["https:\/\/veteran.az\/wp-content\/uploads\/2021\/03\/95016347_984048718677018_8866687943658438656_n-300x261.jpg",300,261,true],"medium_large":["https:\/\/veteran.az\/wp-content\/uploads\/2021\/03\/95016347_984048718677018_8866687943658438656_n-768x667.jpg",640,556,true],"large":["https:\/\/veteran.az\/wp-content\/uploads\/2021\/03\/95016347_984048718677018_8866687943658438656_n.jpg",640,556,false],"1536x1536":["https:\/\/veteran.az\/wp-content\/uploads\/2021\/03\/95016347_984048718677018_8866687943658438656_n.jpg",960,834,false],"2048x2048":["https:\/\/veteran.az\/wp-content\/uploads\/2021\/03\/95016347_984048718677018_8866687943658438656_n.jpg",960,834,false],"covernews-slider-full":["https:\/\/veteran.az\/wp-content\/uploads\/2021\/03\/95016347_984048718677018_8866687943658438656_n.jpg",823,715,false],"covernews-slider-center":["https:\/\/veteran.az\/wp-content\/uploads\/2021\/03\/95016347_984048718677018_8866687943658438656_n-936x834.jpg",561,500,true],"covernews-featured":["https:\/\/veteran.az\/wp-content\/uploads\/2021\/03\/95016347_984048718677018_8866687943658438656_n.jpg",960,834,false],"covernews-medium":["https:\/\/veteran.az\/wp-content\/uploads\/2021\/03\/95016347_984048718677018_8866687943658438656_n-720x380.jpg",540,285,true],"covernews-medium-square":["https:\/\/veteran.az\/wp-content\/uploads\/2021\/03\/95016347_984048718677018_8866687943658438656_n-675x450.jpg",375,250,true]},"author_info":{"display_name":"Veteran.az","author_link":"https:\/\/veteran.az\/?author=3"},"category_info":"Sosial<\/a>","tag_info":"Sosial","comment_count":"0","_links":{"self":[{"href":"https:\/\/veteran.az\/index.php?rest_route=\/wp\/v2\/posts\/8921","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/veteran.az\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/veteran.az\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/veteran.az\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/veteran.az\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8921"}],"version-history":[{"count":1,"href":"https:\/\/veteran.az\/index.php?rest_route=\/wp\/v2\/posts\/8921\/revisions"}],"predecessor-version":[{"id":8923,"href":"https:\/\/veteran.az\/index.php?rest_route=\/wp\/v2\/posts\/8921\/revisions\/8923"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/veteran.az\/index.php?rest_route=\/wp\/v2\/media\/8922"}],"wp:attachment":[{"href":"https:\/\/veteran.az\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8921"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/veteran.az\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8921"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/veteran.az\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8921"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}